BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 30, 2025
Home » Authors » Alfred Romann

Articles by Alfred Romann

New technologies are powering wave of products in Israel

May 25, 2017
By Alfred Romann

Robotics, AI driving elderly med-tech market

May 22, 2017
By Alfred Romann

Pvp Biologics takes on celiac disease with help from Takeda

Jan. 10, 2017
By Alfred Romann
HONG KONG – As part of a unique financing and potential acquisition deal, Pvp Biologics, of San Diego, will work with Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, to fund and speed up the development of a new enzyme that can minimize the negative impact of gluten on celiac disease patients.
Read More

On a scale of 1-10: Earth gets a 3 for infectious disease readiness

Dec. 7, 2016
By Alfred Romann
DOHA, Qatar – Tuberculosis, malaria, pandemic flu and an unknown disease are among the scariest infectious disease threats according to a group of experts gathered in Qatar for a global health summit. And, on a scale of one to 10, the state of readiness of the world to deal with such an outbreak was a resounding three.
Read More

On a scale of 1-10: Earth gets a 3 for infectious disease readiness

Dec. 5, 2016
By Alfred Romann
DOHA, Qatar – Tuberculosis, malaria, pandemic flu and an unknown disease are among the scariest infectious disease threats according to a group of experts gathered in Qatar for a global health summit. And, on a scale of one to 10, the state of readiness of the world to deal with such an outbreak was a resounding three.
Read More

From simple devices to artificial intelligence, med-tech innovation is driving health outcomes

Dec. 1, 2016
By Alfred Romann

Precision med tech moving fast, policy not as quickly

Nov. 30, 2016
By Alfred Romann

Privacy in the genomics age: A unique ethics debate in Islamic world

Nov. 30, 2016
By Alfred Romann
DOHA, Qatar – Advances in genomics have made mapping the genome of individuals both cheap and easy, but those same advances are leading to questions about the suitability of long-held practices of data-based research and a host of concerns of how to develop ethical standards.
Read More

Privacy in the genomics age: A unique ethics debate in Islamic world

Nov. 30, 2016
By Alfred Romann
DOHA, Qatar – Advances in genomics have made mapping the genome of individuals both cheap and easy, but those same advances are leading to questions about the suitability of long-held practices of data-based research and a host of concerns of how to develop ethical standards.
Read More

Toshiba reports record loss, divests medical equipment unit, axes 10K+ jobs

Dec. 23, 2015
By Alfred Romann and Cornelia Zou
HONG KONG – Japan's embattled conglomerate Toshiba Corp. has plans to sell off between half and all of the shares of its medical equipment subsidiary as it restructures its operations in the wake of a multi-billion dollar loss last year.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing